Jasmin Traichel

Jasmin Traichel

Auto-generated profile, based on publicly available information

Jasmin Traichel

University of Freiburg 1 Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine Freiburg, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in Cancer Research Communications
Verified
Journal Article
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Combining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and responding to clinically relevant drugs is essential but unavailable. In this study, we generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations and characterized their ground state and responses to targeted therapy compounds in detail by RNA sequencing, whole-exome sequencing, and various functional assays. Interestingly, these so-called NaJa lines displayed distinct differentiation states and responses to the clinically relevant RAF inhibitors (RAFi) encorafenib and exarafenib, thereby resembling the clinical heterogeneity of BRAFV600E-driven colorectal cancer. RAFi resistance was overcome by the EGFR family inhibitor afatinib. RAFis also influenced the expression of the antigen presentation machinery, cytokines, and other immunomodulatory factors. Upon retransplantation into syngeneic mice, all NaJa lines established aggressive tumors with distinct tumor microenvironments matching their differentiation states. Thus, the NaJa lines provide a unique tool to study tumor heterogeneity, drug resistance, and the interplay between tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer. Significance: We present three newly isolated syngeneic BRAFV600E-driven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
All NaJa cell lines successfully engraft into syngeneic immunocompetent C57BL/6N mice and recapitulate their individual 2D morphologies in vivo. A, Schematic overview of the PVI of NaJa cells (n = 2 NaJa-D, n = 10 NaJa-F, and n = 3 NaJa-G). B, Left, livers showing metastatic nodules 4 weeks after injection (black arrows) and invasive growth in the pancreatic tissue (blue circles). Scale bar, 1 cm. Hematoxylin and eosin: Histology showing that all NaJa cell lines establish tumors (pale blue) in the liver parenchyma (pink) with a differentiation state matching their epithelial or mesenchymal in vitro morphology. Right, IHC and immunofluorescence (IF) staining of proliferation marker Ki-67 (left) and intestinal differentiation markers CDX2 (middle) and E-cadherin (right). L, liver; T, tumor. Scale bar (overview), 500 μm, scale bar (zoom, IHC, and IF), 50 μm. C, Quantification of Ki-67 and CDX2 IHC staining in NaJa cell–induced liver metastases. Each dot represents an individual tumor; different shapes indicate individual tissue sections, and colors denote individual mice. Data are shown as the median ±95% confidence interval (CI).Statistical significance was assessed using the Kruskal–Wallis test followed by Dunn multiple comparison test. **, P < 0.01; ****, P < 0.0001. D, IHC staining of ERK and its downstream target DUSP6. Red arrows indicate examples of nuclear ERK staining. L, liver; T, tumor. Scale bar, 50 μm. [A, Created by J. Traichel in BioRender. Brummer, T. (2025) https://BioRender.com/8ogg64c.]

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Supplementary Figure S3 shows the take rate of orthotopic transplantation of BPAC organoids, PCR confirmation of tumor origin and H&E and IHC images of tumors and metastases.

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Table S3. Apoptosis hallmark genes in RNA-seq of encorafenib-treated NaJa cells

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Supplementary Figure S8 shows comparisons of the baseline transcriptome of NaJa cells, as well as a Western blot of baseline phospho-AKT expression.

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Supplementary Figure S5 shows a Circos plot of the whole-exome sequencing data from NaJa cells and their donor organoid.